Lipid metabolism

OMEOlipid by EPO

EPO's OMEOlipid is a combination of Artichoke (Cynara scolymus L.), Caihua (Cyclanthera pedata (L.) Schrad.) and Greek Fenu (Trigonella foenum-graecum L.) with anti-cholesterol and cholagogue properties.

A new study published in Frontiers in Pharmacology confirms the anti-cholesterol efficacy of artichoke, caigua and fenugreek plant extracts and their original mixture. Dyslipidaemia and hypercholesterolaemia are among the main causes of cardiovascular disease: nutraceutical formulas with anti-cholesterol activity, such as OMEOlipid, may be useful in the prevention and treatment of hypercholesterolaemia, representing a valid alternative to current therapies such as statin administration and monacolin K.

OMEOlipid combines the traditions of three different countries:

The artichoke is a Mediterranean plant; its cultivation in Europe dates back to ancient Greece and Rome. Its active substances (caffeoylquinic acids, flavonoids, sesquiterpene lactones) are concentrated in the leaf, acting as a digestive, cholagogue, hepatoprotective and depurative.

Caihua is a traditional South American plant; the fruit contains flavonoids and in Peru its use has been documented since 3700 BC as a hypotensive, anti-diabetic, anti-inflammatory and hypocholesterolemic.

Greek fenu is a landmark of Ayurvedic medicine, it relieves kapha and vata. The seeds contain saponins, coumarins, flavonoids and alkaloids. They have cholesterol-lowering, diuretic, diaphoretic, carminative, hypoglycaemic, demulcent properties and are traditionally used to treat obesity and diabetes.

Thanks to the perfect combination of the beneficial properties of the three plants, OMEOlipid can be used in food supplements for its anti-cholesterol and cholagogue properties.

It has strong hepatoprotective, antioxidant and depurative effects and supports liver function.

It also promotes the production and flow of bile, which is essential for the elimination of cholesterol, and reduces intestinal absorption of cholesterol and thus its uptake.

OMEOlipid acts as a hypoglycaemic and hypotensive and alleviates problems related to kidney dysfunction.

EPO's Omeolipid is distributed in Spain by Deltapharma, part of Faravelli Group.
For more info, please get in touch